Month: May 2020

Due to the COVID-19 pandemic and the restrictions imposed, Novaturas Group has suspended its operations since the second half of March. Restrictions imposed have resulted in Novaturas Group not generating turnover in April this year. During the same period in 2019, the Company has reached a turnover of EUR 14.4 million and served 23.7 thousand travellers.In order to manage the situation caused by COVID-19, Novaturas Group has taken strict cost-saving measures, negotiated with business partners abroad, and uses a state aid measure that allows it to compensate part of the employees’ salaries. The company is also expecting the final decisions of the Lithuanian government on aid measures to ensure liquidity. While expecting state aid, the Company is also looking for alternative sources of financing.In assessing possible future scenarios,...

Dėl COVID-19 sukeltos pandemijos ir jai įveikti įvestų apribojimų „Novaturo“ grupė nuo kovo mėn. antrosios pusės tebėra laikinai sustabdžiusi kelionių organizavimą. Dėl pandemijos įvesti apribojimai lėmė, kad 2020 m. balandį bendrovė nesugeneravo apyvartos, kai tuo metu pernai ji sudarė 14,4 mln. eurų, aptarnautų klientų skaičius siekė 23,7 tūkst.Valdydama COVID-19 sukeltą situaciją, „Novaturo“ grupė ėmėsi griežto kaštų taupymo veiksmų, derasi su verslo partneriais užsienio šalyse, naudojasi valstybės teikiama pagalbos priemone, kuri leidžia kompensuoti dalį darbuotojų darbo užmokesčio. Bendrovė taip pat laukia galutinių Lietuvos vyriausybės sprendimų dėl pagalbos priemonių turizmo verslo likvidumui užtikrinti, kuriomis ketina naudotis, ieško alternatyvių finansavimo šaltinių.Vertindama galimus ateities scenarijus, Bendrovė remiasi atsakingų...

Stockholm, Sweden – Sinch AB (publ) – XSTO: SINCHSinch held its annual general meeting on Friday 15 May 2020 at 2.00 p.m. in the meeting venue Kungsholmen 2, Hotell Courtyard by Marriott Stockholm, Rålambshovsleden 50, Stockholm, Sweden.Adoption of financial statements, appropriation of the company’s profit or loss and discharge from liabilityThe meeting adopted the presented profit and loss statement and balance sheet as well as the consolidated profit and loss statement and consolidated balance sheet.In accordance with the proposal of the board of directors, the meeting resolved to not pay any dividend for the financial year 2019.The meeting further resolved to grant discharge from liability of the members of the board of directors, the CEO and the deputy CEO for the financial year 2019.Election of members of the board of directors,...

Stockholm, Sverige – Sinch AB (publ) – XSTO: SINCHSinch höll fredagen den 15 maj 2020 kl. 14.00 årsstämma i lokalen Kungsholmen 2, Hotell Courtyard by Marriott Stockholm, Rålambshovsleden 50, Stockholm.Fastställelse av resultat- och balansräkningar, dispositioner beträffande bolagets resultat och ansvarsfrihetStämman beslutade att fastställa framlagda resultat- och balansräkningar samt koncernresultaträkning och koncernbalansräkning.I enlighet med styrelsens förslag beslutades att inte lämna någon utdelning för räkenskapsåret 2019.Stämman beslutade vidare om ansvarsfrihet för styrelsen, den verkställande direktören och den vice verkställande direktören för räkenskapsåret 2019.Val av styrelse, styrelseordförande och revisorerÅrsstämman beslutade, i enlighet med valberedningens förslag, att styrelsen ska bestå av fem stämmovalda ledamöter...

OTTAWA, May 15, 2020 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSXV:TBP) (OTCQB:TBPMF), is pleased to announce that, in connection with its previously announced overnight marketed offering, a syndicate of agents led by Raymond James Ltd. and Canaccord Genuity Corp. (collectively, the “Agents”), have agreed to sell 33,089,000 units (“Units”) of the Company at a price of $0.26 per Unit (the “Issue Price”) for aggregate gross proceeds of approximately $8.6 million (the “Offering”). Each Unit will consist of one common share in the capital of Tetra (a “Common Share”) and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to acquire one Common Share at a price of $0.32 for a period of 36 months from the closing date of...

(UPM, Helsinki, 15 May 2020 at 17:40 EET) – UPM is proceeding at full speed with its investment project in Uruguay and has taken several steps forward. UPM and the new Government of Uruguay have signed a memorandum of understanding on pending items related to UPM’s growth project in Uruguay that will further strengthen the implementation of UPM’s growth project and existing operations in Uruguay as well as the local economy.Especially in the context of the COVID-19 pandemic and its potential impacts on Uruguayan society, UPM and the Government of Uruguay recognize the critical importance of ensuring the implementation of the project and realizing its benefits for the Uruguayan economy.Both parties are fully committed and implementing the existing investment agreement signed between UPM and the previous Government of Uruguay in November...

(UPM, Helsinki, 15.5.2020 klo 17.40 EET) – UPM vie kasvuhankettaan eteenpäin Uruguayssa täydellä vauhdilla. UPM ja Uruguayn uusi hallitus ovat sopineet UPM:n kasvuhankkeeseen liittyvistä avoimista asioista, jotka vahvistavat entisestään niin kasvuhankkeen toteutusta, UPM:n nykyisiä toimintoja Uruguayssa kuin paikallista taloutta.UPM ja Uruguayn hallitus näkevät kasvuhankkeen toteutuksen ja siitä Uruguaylle koituvien taloudellisten hyötyjen varmistamisen erittäin tärkeiksi etenkin huomioiden COVID-19 pandemia ja sen mahdolliset vaikutukset Uruguayn talouteen.Molemmat osapuolet ovat sitoutuneita investointisopimukseen, jonka UPM ja Uruguayn edellinen hallitus allekirjoittivat marraskuussa 2017. Hankkeen menestyksekäs toteuttaminen edellyttää useita rakennustöihin, infrastruktuuriin, energiaan ja alueellisen kehitykseen liittyviä asioita,...

Örugg orkuvinnsla á tímum heimsfaraldursHelstu atriði árshlutareikningsHagnaður fyrir óinnleysta fjármagnsliði nam 44,0 milljónum USD (6,3 ma.kr.), en var 50,5 milljónir USD á sama tímabili árið áður og lækkar því um  12,7% milli tímabila.Hagnaður tímabilsins var 31,5 milljónir USD (4,5 ma.kr.) en var 41,2 milljónir USD á sama tímabili árið áður.Rekstrartekjur námu 126,2 milljónum USD (17,9 ma.kr.) og lækka um 7,0 milljónir USD (5,3%) frá sama tímabili árið áður.Nettó skuldir lækkuðu um 54,2 milljónir USD (7,7 ma.kr.) frá áramótum og voru í lok mars 1.637,3 milljónir USD (232,5 ma.kr.).   Handbært fé frá rekstri nam 75,4 milljónum USD (10,7 ma.kr.) sem er 10,2% lækkun frá sama tímabili árið áður.Hörður Arnarson, forstjóri:„Afkoman á fyrsta ársfjórðungi er vel viðunandi í ljósi þess að ytri aðstæður voru áfram krefjandi í rekstri Landsvirkjunar,...

Secure power generation in pandemic timesKey figures from the interim financial statementsProfit before unrealised financial items amounted to USD 44.0 million compared to USD 50.5 million in the same period of the prior year which is a decrease of 12.7%.The profit for the period was USD 31.5 million compared to USD 41.2 million in the same period of the prior year.Operating revenues amounted to USD 126.2 million decreasing by USD 7.0 million (5.3%) from the same period of the prior  year.Net debt decreased by USD 54.2 million from the beginning of the year and amounted to USD 1,637.3 million at the end of March.Cash flow from operations amounted to USD 75.4 million which is a decrease of 10.2% compared to the same period of the prior year.Hörður Arnarson, CEO:“The first quarter results were acceptable in light of the challenging...

NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the appointment of Judith Dunn, Ph.D. to its Board of Directors.Dr. Dunn has had an extensive career in the pharmaceutical and biotechnology industries having served in various roles at F. Hoffman-La Roche AG from March 2010 through January 2018, including Vice President, Global Head of Clinical Development and Principal Medical Group Leader, Neuroscience. She also served as the Executive Medical Director, CNS Clinical Development (Ph I-III) at Sepracor, Inc. from 2005 to 2010 and in a number of roles at Pfizer Inc. from 1997 to 2005, including Director, Worldwide Medical Affairs, Antipsychotics,...